InMode

Company Overview

Snapshot

Founded in January 2008 by Moshe Mizrahy, InMode operates with over 500 employees. The company has raised $70 million across one funding round and went public on NASDAQ in August 2019.

Business overview

InMode is a global provider of energy-based minimally invasive and noninvasive aesthetic solutions, leveraging medically accepted radio-frequency (RF) energy technology. Its products are designed to penetrate deep into the subdermal fat layer for adipose tissue remodeling. Physicians utilize InMode's technologies for various procedures, including liposuction with simultaneous skin tightening, face and body contouring, and ablative skin rejuvenation treatments, serving the health tech and life sciences sector with solutions like BodyTite, Optimas, Votiva, Contoura, EmbraceRF, Evoke, Evolve, and Triton workstations.

Strategic signal

In September 2025, DOMA Perpetual sent a letter urging. This signals a potential shift in the company's financial strategy towards shareholder returns, which could impact future investment decisions and operational priorities.

Company Intelligence Q&A

When did InMode go public?

InMode went public on NASDAQ in August 2019.

What was InMode's last disclosed funding amount?

InMode's last disclosed funding amount was $70 million, raised in a single funding round prior to its IPO.

What was a significant corporate development for InMode in July 2023?

In July 2023, InMode expanded its women's health and wellness market footprint through the acquisition of Viveve Medical's patents.

What was a key investor-related event for InMode in September 2025?

In September 2025, DOMA Perpetual sent a letter urging InMode's Board of Directors to return capital to shareholders, highlighting a focus on capital allocation.

What was InMode's Q3 2024 earnings call highlight?

InMode's Q3 2024 earnings call highlighted navigating challenges with strategic adjustments and revenue growth amidst these challenges.